Physician profile
Nasser Taghavi
NPI 1487624383
$4,859.84
in general payments reported to CMS, 2019-2025
29 companies · $547 in 2025
The $547 reported for 2025 was more than what 80% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $243 · 2020: $601 · 2021: $654 · 2022: $798 · 2023: $1,335 · 2024: $682 · 2025: $547.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,540 · Education: $23.42.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,540.35 |
| Education | $23.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $690.95 | 2021-2025 | Vraylar, Mavyret |
| Lilly USA, LLC | $677.67 | 2020-2025 | Mounjaro, Jardiance, Emgality |
| Astrazeneca Pharmaceuticals LP | $531.91 | 2019-2025 | Breztri, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $332.85 | 2020-2025 | Jardiance |
| Teva Pharmaceuticals USA, INC. | $315.89 | 2023-2025 | Austedo Xr, Austedo Xr, Austedo |
| Allergan, INC. | $266.93 | 2020 | |
| Uswm, LLC | $255.13 | 2022-2024 | Lucemyra, Zimhi |
| Glaxosmithkline, LLC. | $227.49 | 2020-2025 | Trelegy Ellipta |
| Pfizer INC. | $197.13 | 2019-2024 | |
| Indivior INC. | $178.57 | 2023-2025 | Sublocade |
| Amgen INC. | $167.50 | 2021-2024 | Repatha, Otezla, Prolia |
| Janssen Pharmaceuticals, INC | $139.07 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $117.28 | 2020-2023 | |
| Neurocrine Biosciences, INC. | $97.09 | 2024-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $90.27 | 2023-2025 | Rexulti |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $79.55 | 2023-2024 | Cologuard Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $73.56 | 2024-2025 | Caplyta |
| Sumitomo Pharma America, INC. | $69.23 | 2023-2024 | Gemtesa, Aptiom |
| Merck Sharp & Dohme LLC | $55.38 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $47.00 | 2019-2023 | Xifaxan |
| Novo Nordisk INC | $45.46 | 2020-2022 | |
| Orexo US, INC. | $39.94 | 2024-2025 | Zubsolv |
| Idorsia Pharmaceuticals US INC | $36.05 | 2022-2023 | Quviviq |
| Urovant Sciences INC | $33.76 | 2021-2022 | |
| Abbott Laboratories | $33.35 | 2023-2025 | Freestyle Libre 3 |
| Biohaven Pharmaceuticals, INC. | $20.26 | 2021 | |
| Gilead Sciences, INC. | $14.61 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $13.88 | 2021 | |
| Acadia Pharmaceuticals INC | $12.08 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nasser Taghavi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.